Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 15, 2026Blood ScienceOpen Access

Orelabrutinib with anti-CD20 monoclonal antibodies is highly effective and well-tolerated as first-line therapy for marginal zone lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

NYNa YaoBeijing Tongren HospitalCWCe WangWannan Medical CollegeJCJia CongBeijing Tongren Hospital

Discussion

Loading...

Member takes

Overview

This retrospective study shows promising overall response rates in marginal zone lymphoma, suggesting a well-tolerated treatment option.

Key Points

  • The study aims to evaluate the effectiveness and safety of orelabrutinib combined with anti-CD20 monoclonal antibodies in treatment-naïve patients with marginal zone lymphoma.
  • Retrospective analysis of 25 treatment-naïve patients with marginal zone lymphoma.
  • Patients received orelabrutinib plus either rituximab or obinutuzumab for 6 cycles.
  • Orelabrutinib maintenance was administered for up to 6 months.
  • Overall response rate was assessed based on the 2014 Lugano criteria.
  • Achieved an overall response rate of 96%, including 12 complete responses and 12 partial responses.
  • No significant difference in complete response rates between rituximab and obinutuzumab groups.
  • 32% of patients experienced treatment-related adverse events, mostly neutropenia and thrombocytopenia.
  • Grade 3 to 4 adverse events occurred in 12% of patients.

Cite This Study

Yao et al. (2026) studied this question.

synapsesocial.com/papers/69df2b65e4eeef8a2a6b067dhttps://doi.org/10.1097/bs9.0000000000000286
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy, safety, and genetic analysis of orelabrutinib combined with rituximab as first-line systemic treatment for marginal zone lymphoma.2026
  2. 2Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  3. 3Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  4. 4Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025
  5. 5Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations